Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction

Am J Cardiol. 2004 Jun 1;93(11):1438-40, A10. doi: 10.1016/j.amjcard.2004.02.052.

Abstract

In 15 patients with chronic heart failure of ischemic origin who were not previously treated with angiotensin-converting enzyme inhibitors, platelets exhibited hyperaggregability and impaired responsiveness to the antiaggregatory and cyclic guanosine monophosphate-stimulatory effects of nitric oxide donor sodium nitroprusside compared with normal subjects; this was paralleled by increased blood levels of superoxide radicals. Treatment with perindopril for 4 days significantly improved platelet responses to sodium nitroprusside; there was also a trend toward a decrease in superoxide radical levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Cyclic GMP / blood
  • Female
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / pharmacology*
  • Nitric Oxide Donors / pharmacology
  • Nitroprusside / pharmacology
  • Perindopril / therapeutic use*
  • Platelet Aggregation / drug effects*
  • Platelet Function Tests
  • Superoxides / blood
  • Time Factors
  • Ventricular Dysfunction, Left / complications*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Nitric Oxide Donors
  • Superoxides
  • Nitroprusside
  • Nitric Oxide
  • Cyclic GMP
  • Perindopril